Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin for disorders of consciousness after coma
2021-006486-38Phase 2Terminated
- Sponsor
- University of Liège
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of psilocybin in disorder of consciousness (DOC), vegetative state (VS), Minimally conscious state (MCS) and 1 more, sponsored by University of Liège. Primary endpoint: New signs of consciousness (SECONDs). Started Jun 2022; status: terminated.
02
Drugs
psilocybin
03
Conditions
disorder of consciousness (DOC)vegetative state (VS)Minimally conscious state (MCS)acquired brain injury (ABI)
Beyond the preview
Go deeper on 2021-006486-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006486-38.